Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: J Mol Cell Cardiol. 2011 Feb 24;50(5):841–848. doi: 10.1016/j.yjmcc.2011.02.003

Figure 4. Fluorescein-conjugated CSTSMLKAC concentrated in cardiomyocytes in ischemia-reperfusion injured myocardium.

Figure 4

Following ischemia-reperfusion injury, rats were treated with 1 mg of either fluorescein-CSTSMLKAC (A, B and C) or fluorescein-scrambled peptide (D, E and F) by intravenous injections. Hearts and aortic tissues were harvested and fixed 10 minutes after injection. Histological sections were stained with Isolectin-IB4 to stain endothelium (red) and DAPI to stain nuclei (blue). Panel A and D show the anterior wall of left ventricle (LV) of the ischemic region, and B and E show the posterior wall of LV of the non-ischemic region. Fluorescein-CSTSMLKAC (green), but not scrambled peptide, was concentrated in cardiomyocytes in the injured myocardium, while fluorescein-CSTSMLKAC did not concentrate in cells in aortic tissues (C and F). Scale bars represent 50 μm.